- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07776405
A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis
Topical Cannabidiol for Plantar Fasciitis: A Double-Blinded Study on Rapid and Sustained Pain Relief
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Plantar fasciitis is one of the most common causes of plantar heel pain, affecting millions of adults annually and accounting for a large proportion of musculoskeletal complaints seen in orthopaedic and sports medicine clinics. The condition is typically caused by repetitive microtrauma and inflammation at the plantar fascia's insertion on the calcaneus, leading to chronic pain, functional impairment, and limitations in daily activities. Despite its prevalence, effective and well-tolerated long-term treatments remain limited. Current management strategies, including stretching, orthotics, corticosteroid injections, and physical therapy, often provide only temporary relief or are associated with adverse effects from repeated use.
Cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from hemp, has gained attention for its potential anti-inflammatory and analgesic properties. Preclinical and clinical studies have demonstrated CBD's ability to modulate inflammatory markers, reduce cytokine activity, and improve pain perception in various musculoskeletal and neuropathic conditions. These mechanisms make it a promising candidate for targeting inflammation-driven pain disorders such as plantar fasciitis. Although CBD has been studied for arthritis, tendon injuries, and generalized pain syndromes, no published trials have yet evaluated its efficacy in plantar fasciitis specifically.
A recent scoping review on topical CBD interventions confirmed this absence of evidence, highlighting a significant gap in the current literature regarding CBD's role in localized foot and heel pain. This lack of research underscores an unmet clinical need to assess whether transdermal delivery of CBD could provide measurable short- and long-term benefits in patients with plantar fasciitis.
This study aims to address that gap by evaluating a 6000 mg transdermal CBD cream (Tolcylen®, Marlinz Pharma) for both immediate and sustained pain reduction in adults with plantar fasciitis. By using a randomized, double-blinded, placebo-controlled design, we intend to determine whether topical CBD can offer a safe, non-invasive, and effective alternative or adjunct to current treatments. The results of this investigation may contribute to the emerging evidence on topical cannabinoids in orthopaedic pain management and inform future clinical practice guidelines.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Shea Herlihy, MS
- Numéro de téléphone: 352-273-7361
- E-mail: herliso@ortho.ufl.edu
Sauvegarde des contacts de l'étude
- Nom: Antony Merendino, DPM
- Numéro de téléphone: 352-273-7044
- E-mail: merena@ortho.ufl.edu
Lieux d'étude
-
-
Florida
-
Gainesville, Florida, États-Unis, 32611
- University of Florida Department of Orthopaedics
-
Contact:
- Shea Herlihy, MS
- Numéro de téléphone: 352-273-7361
- E-mail: herliso@ortho.ufl.edu
-
Contact:
- Antony Merendino, DPM
- Numéro de téléphone: 352-273-7044
- E-mail: merena@ortho.ufl.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Patients aged 18-85
- Clinical diagnosis of plantar fasciitis by a qualified provider
- Symptomatic for at least four weeks with plantar heel pain consistent with plantar fascia involvement
- Baseline average pain score that meets eligibility threshold as defined in the protocol (?)
- Willing to apply assigned cream once daily and attend needed visits (?)
Exclusion Criteria:
- Special populations and consent limitations. Pregnancy, breastfeeding, prisoners, inability to provide informed consent, or inability to complete study procedures
- Contraindications to topical products or CBD. History of allergy or sensitivity to cannabinoids, excipients, or topical creams used in the study
- Confounding dermatologic conditions at the application site. Open wounds, active infection, dermatitis, ulceration, or recent burns on the heel or midfoot
- Recent or planned procedures that alter outcomes. Corticosteroid injection, platelet rich plasma, surgery, immobilization, or shockwave therapy within the protocol washout window
- Concurrent therapies that confound pain outcomes. Routine use of systemic opioids, regular use of nonsteroidal anti-inflammatory drugs beyond rescue parameters, new analgesic starts during the study, or use of other topical analgesics on the study area
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Participants who receive a transdermal cannabidiol cream
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month
|
The active product is the study CBD cream supplied by the manufacturer.
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month.
The first dose will be taught and supervised in clinic using a glove.
The cream will be massaged into the affected area for at least forty-five seconds.
Skin must be clean and dry before application.
No other topical agents may be placed on the study area during the study period.
|
|
Comparateur placebo: Participants who receive a matched placebo
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month
|
The control group will receive a placebo cream identical in appearance, texture, scent, and packaging to the active product but containing no cannabidiol.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
• Immediate pain relief, measured by change in numeric rating scale (0-10) from baseline to ten minutes after supervised application.
Délai: Daily for one month
|
Daily for one month
|
|
|
• One-month changes in average daily pain score compared to baseline.
Délai: Daily for one month
|
Daily for one month
|
|
|
• Global patient satisfaction
Délai: Daily for one month.
|
measured using a five-point Likert scale assessing overall perceived improvement.
|
Daily for one month.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Duration of immediate pain relief following initial application
Délai: Daily for one month
|
Daily for one month
|
|
|
Adherence to protocol measured by patient logs and pump counts
Délai: Daily for one month
|
Daily for one month
|
|
|
Incidence of adverse effects
Délai: Daily for one month
|
Occurrence of negative side effects
|
Daily for one month
|
|
Rescue analgesic use
Délai: Daily for one month
|
Daily for one month
|
|
|
Time to perceived improvement in symptoms
Délai: Daily for one month
|
Daily for one month
|
|
|
6. PROMIS Pain Interference questionnaire
Délai: At enrollment and at end of once month
|
At enrollment and at end of once month
|
|
|
7. Foot Function Index questionnaires
Délai: At enrollment and at one month
|
At enrollment and at one month
|
|
|
8. Return to normal activity - the number of days required for participants to resume full standing or walking tolerance without pain
Délai: Once during one month
|
Once during one month
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB#: 202501843
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .